Haute Capital Partners portfolio company BioCopy AG has released the first public description of ValidaTe®, its AI-driven discovery platform for safer cancer immunotherapies.

The ETH Zurich spin-off extends its seed financing three years after the CHF 1.8 million round led by Haute Capital Partners.

Haute has published the first research paper supported under its academic research programme. The study provides one of the first empirical assessments of autonomous AI agents operating in financial markets. Through this initiative, Haute aims to support rigorous scientific research that advances the understanding of emerging technologies and provides the foundation for future products and investment solutions grounded in empirical evidence.

Haute Capital Partners SA (BX Swiss: HAUTE) announces the acquisition of 420,000 shares of Exentis Group AG. The consideration consists of 89,297 treasury shares of Haute Capital Partners SA, valued at CHF 55.50 per share, representing a transaction value of CHF 4,955,984.